Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Patent Expiry of Blockbuster Drugs and Push for Lower Healthcare Costs Drive Generic Pharmaceuticals Market
- PALO ALTO, Calif. -- With several major blockbuster drugs reaching patent expiry, the market for generic pharmaceuticals in the United States is booming and is set to witness significant growth over the next few years. Demand for lower healthcare costs and pressure from payers to increase the use of generics...
- Research articles 2007-08-15
- Bitter pill; Pharmaceuticals.(Pfizer Inc.)(Brief article)
- The failure of a future blockbuster drug squeezes Pfizer The failure of a future blockbuster drug squeezes Pfizer
- Research articles 2006-12-09
- AstraZeneca ruling kicks rivals into touch.
- AstraZeneca's ulcer treatment blockbuster drug will be free of low cost generic competitors until 2015 Richard Hemming AstraZeneca's ulcer treatment blockbuster drug will be free of low cost generic competitors until 2015 Richard Hemming
- Research articles 2007-10-12
- GLAXOSMITHKLINE (GSK).
- Generic versions of blockbuster drugs have been a major headache for all the big pharmaceutical firms. But GlaxoSmithKline's GSK chief executive, JP Garnier, believes that the group's strong product pipeline is helping it fight back. "We're ab Generic versions of blockbuster drugs have been a major...
- Research articles 2007-02-16
- Clarinex ready to go ; Schering preps marketing effort while waiting for FDA green light.
- Schering-Plough will use a futuristic logo to introduce its eagerly anticipated successor to the blockbuster drug Claritin, now in the final stages of government approval. Schering-Plough will use a futuristic logo to introduce its eagerly anticipated successor to the blockbuster drug Claritin, now in...
- Research articles 2001-01-29
- FDA Approves Use of Eli Lilly Drug for Manic Depression.(Knight Ridder/Tribune Business News)
- Mar. 18--INDIANAPOLIS--Eli Lilly and Co. soon might have a new best-selling drug to top Prozac, the blockbuster drug that put Lilly on the map and revolutionized the treatment of depression. Mar. 18--INDIANAPOLIS--Eli Lilly and Co. soon might have a new best-selling drug to top...
- Research articles 2000-03-20
- CHANGING CLIMATE: UNCERTAINTY COOLS INTEREST IN DRUG COMPANY STOCKS; POLITICS, LACK OF NEW MEDICINES HAS SOME WARY.
- Meddling by President Clinton and a lack of blockbuster drugs in the pipeline raise red flags for institutional managers investing in the drug industry. Large-cap pharmaceutical companies such as Pfizer Inc. and Merck & Co. Inc. have been popu Meddling by President Clinton...
- Research articles 1999-03-08
Additional Resources
- Comcast upgrading residential broadband and Amgen's next blockbuster drug.
- M2 PRESSWIRE-24 January 2005-FNWU: Comcast upgrading residential broadband and Amgen's next blockbuster drugC1994-2005 M2 COMMUNICATIONS LTD RDATE:01242005 City of Industry, CA - Market leaders reported on by Financial News USA. Integrated circuit maker Linear Technology Corp. (NASDAQ: LLTC), said on...
- Research articles 2005-01-24
- DDB shop gets J&J's Procrit; $50 million drug account moves to Anderson from WPP's OgilvyOne.(Aderson Advertising wins Johnson and Johnson advertising contract)(Brief Article)
- Johnson & Johnson is quietly consolidating an estimated $50 million-plus account for blockbuster drug Procrit at DDB Worldwide network shop Anderson Advertising, Toronto, replacing Ogilvy & Mather Worldwide's OgilvyOne, New York. Johnson & Johnson is quietly consolidating an estimated $50 million-plus account for...
- Research articles 2001-10-15
- NEJM: Foreign Drug Trials Could Hurt U.S. Patients
- The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...
- Blog posts 2009-02-19
- Mayne needs blockbuster drug to maintain growth.
- May 27, 2003 (The Australian Financial Review - ABIX via COMTEX) Australian diversified hospitals and health group, Mayne, needs a "blockbuster" new drug. This was the opinion of analysts on 27 May 2003 in assessing Mayne's likely profits for 2002-03 and 2003-04. UBS Warburg's...
- Research articles 2003-05-27
- J&J Avoids Limit For Blockbuster Drug
- New Brunswick's Johnson & Johnson got encouraging news last week for its $3.2-billion drug Procrit, which is used to manage anemia in patients with chronic renal failure. An expert panel of the Food and Drug Administration voted against setting a target limit for hemoglobin levels for patients with chronic kidney...
- Research articles 2007-09-17
- Key Akzo drug launch delayed. (News Briefs).(Brief Article)
- Akzo Nobel says it will not be able to launch its new antidepression drug Ariza as expected this year, following efficacy questions by FDA. Analysts have tipped Ariza as a potential blockbuster drug with peak sales of [euro]500 million ($440 million)/year. FDA wrote to Akzo's U.S....
- Research articles 2002-04-17
- Finding the Next Blockbuster Drug.
- This has been a record year for the drug industry. It saw what would have been one of the largest mergers in its history-a $23 billion merger between American Home Products and Monsanto-called off, the most successful initial product launch ever in This has...
- Research articles 1998-11-23
- Immunex Plans $500 Million Plant in Rhode Island to Boost Output of Star Drug.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Aug. 15--Immunex is planning to spend $500 million to build a high-yield factory to greatly boost the production of its blockbuster drug, Enbrel. It will take four years for the Seattle...
- Research articles 2001-08-15
- Vivus's Qnexa Drug Approval Makes It a Nice Trade
- Here are Wednesday's articles concerning Vivus Inc's VVUS FDA approval for Qnexa. I see this as a blockbuster drug candidate and good news for the nearly 40M Obese Americans. My only caution is later health problems as it uses some form of the fen-phen medication. This is a nice trade...
- External links 2009-09-10
- Research and Markets: From 2005 to 2008, Total Blockbuster Sales Are Forecast to Demonstrate A CAGR of Only 1.6% Compared With The 9% Forecast for the Period 2002 To 2005
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c20074) has announced the addition of Beyond the Blockbuster Drug: Strategies for Nichebuster Drugs, Targeted Therapies and Personalized Medicine to their offering.
- Research articles 2005-06-30
- Genetic Engineering News' Poll Indicates Blockbuster Drug Reign Unlikely to End Soon
- Business Editors LARCHMONT, N.Y.--BUSINESS WIRE--April 30, 2004 Despite the increasing amount of R&D on personalized medicine, blockbuster drugs will remain the main goal for many pharmaceutical firms, according to a recent Genetic Engineering News GEN website poll (www.genengnews.com). Three-hundred-and-forty-four individuals answered the poll, the results of which appear...
- Research articles 2004-04-30
- Resverlogix: Canadian Biotech Blockbuster
- Jim Letourneau submits: The world’s next blockbuster drug might be coming out of a company based in my hometown of Calgary, Alberta, Canada. The company is called Resverlogix (RVXCF.PK) (RVX.TO) and I had the opportunity to meet with the company’s president, Don McCaffrey, back in February of this...
- External links 2009-10-06
- Safety Officials Get a Seat at the Drug-Regulation Table
- The pharmaceutical industry is finally facing one of its worst-case scenarios: FDA's drug-safety officials will now hold considerably more sway over both experimental and approved drugs. Prodded by Congress in the wake of several major drug-safety and effectiveness concerns --Â starting, perhaps, with Vioxx, and since expanded...
- Blog posts 2008-07-01
- << Previous
- page 1 of 1
- Next >>
